РОЛЬ СОВРЕМЕННЫХ БИОМАРКЕРОВ В ОЦЕНКЕ ПРОФИБРОЗНЫХ ПРОЦЕССОВ ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ
Kalit so'zlar
https://doi.org/10.47390/Med-pro/v3i7y2025/N07Kalit so'zlar
системная склеродермия, фиброз, биомаркеры, TGF-β1, эндотелин-1, MMP-9, TIMP-1, CTGF, легочный фиброз, фиброгенез.Annotasiya
Изучена диагностическая и прогностическая значимость биомаркеров фиброгенеза (TGF-β1, эндотелин-1, MMP-9, TIMP-1, CTGF) у 37 больных системной склеродермией. Повышение TGF-β1, TIMP-1 и CTGF коррелировало с кожным и лёгочным фиброзом. Эти маркеры отражают активность профиброзных процессов и могут использоваться для мониторинга течения ССД.
Manbalar
1. Allanore Y., et al. Biomarkers in systemic sclerosis: an update. Autoimmun Rev. 2022;21(4):103051.
2. Asano Y. The pathogenesis of systemic sclerosis: An understanding based on recent progress in research. J Dermatol. 2021;48(1):31–43.
3. Buranova, S. N., Akhmedov, Kh. S., Razakova, F. S. Cartilage oligomeric matrix protein (COMP) in early diagnosis of osteoarthritis. The Chinese Journal of Occupational Diseases of Labor and Health, 39(7), 93–100 (2021).
4. Buranova, S. N., Akhmedov, Kh. S., Razakova, F. S. The Importance of Treatment Aimed at the Dynamics of Cartilage Oligomer Matrix Protein (COMP) in Patients with the Knee Joint Osteoarthritis. American Journal of Medicine and Medical Sciences, 11(2), 148–153 (2021).
5. Distler O., et al. Pathophysiology of systemic sclerosis: current understanding and future directions. Nat Rev Rheumatol. 2019;15(12):765–781.
6. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989–2003.
7. Khalmetova, F. I., Akhmedov, X. S., Alibekova, G. A. Features of the course of the joint syndrome in various forms of reactive arthritis. Galaxy International Interdisciplinary Research Journal, 11(4), 832–837 (2023).
8. Kuwana M., et al. Clinical relevance of serum endothelin-1 and its receptors in systemic sclerosis. Arthritis Rheum. 2018;70(4):620–631.
9. Mahoney J.M., et al. CXCL4: a biomarker of early systemic sclerosis. N Engl J Med. 2015;372(4):233–243.
10. Rakhimova M.B. Impaired endothelial dysfunction in COVID-19. J Med Life Sci. 2023;4(1):55–60.
11. Rakhimova M.B., et al. Endothelin-1 biomarker features in patients with ankylosing spondylitis after COVID-19. J Positive School Psychology. 2022;6:6–12.
12. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35–42. Van Bon L., et al. Connective tissue growth factor and fibrosis in systemic sclerosis. Ann Rheum Dis. 2014;73(10):1834–1841.
